Valeant taps Parexel to shepherd retigabine regulatory filings
This article was originally published in Pharmaceutical Approvals Monthly
Valeant's planned mid-2008 NDA and MAA submissions for the anti-epileptic retigabine will be managed by Parexel. The contract services organization will "develop, coordinate and prepare" the NDA as well as the European MAA, Valeant says. Retigabine, a neuronal potassium-channel opener, is being studied in two international Phase III studies - RESTORE1 and RESTORE2 - as an adjunct treatment for partial onset seizures in patients with refractory epilepsy. Pharmaceutical Approvals Monthly erred in identifying the Phase III program in a previous story (1Pharmaceutical Approvals Monthly May 2007, p. 7). Valeant announced the initiation of a Phase IIa study of retigabine treatment of pain associated with post-herpetic neuralgia on May 31; the proof-of-concept study will enroll 180 patients...
You may also be interested in...
While a chemotherapy-induced neuropathic pain indication is in development, Valeant is relaunching the synthetic cannabinoid Cesamet with a new strategy for its approved antiemetic use that will focus on physicians treating breast cancer at high-volume teaching institutions, President-Valeant North America/R&D Wesley Wheeler told a May 1 earnings call
Pfizer will aim to have its biosimilar Neulasta (pegfilgrastim) product, Nyvepria, on the market in both the EU and US by the end of the current quarter, a company spokesperson has informed Generics Bulletin, following a successful US launch.
With a biosimilar Lucentis (ranibizumab) candidate recently filed and Soliris (eculizumab), Eylea (aflibercept) and Prolia (denosumab) candidates in Phase III development, Samsung Bioepis has moved into its new domestic headquarters to spearhead its journey to the next level.